Andrew M Kaunitz, MD, FACOG
Professor; Associate Chair, Department of Obstetrics And Gynecology; Medical Director, UF Health Women's Specialits – Emerson
Department:
Obstetrics and Gynecology – Jacksonville
Business Phone:
(904) 244-3109
Business Email:
andrew.kaunitz@jax.ufl.edu
About Andrew M Kaunitz
Andrew Kaunitz, M.D., FACOG, is a University of Florida professor of obstetrics and gynecology, and a board-certified obstetrician-gynecologist at UF Health in Jacksonville. He also serves as associate chair of the UF Department of Obstetrics and Gynecology – Jacksonville, as well as medical director of UF Health Women’s Specialists – Emerson. Dr. Kaunitz received his medical degree from Columbia University College of Physicians and Surgeons in New York, New York, and completed his residency in obstetrics and gynecology at Northwestern Memorial Hospital in Chicago, Illinois. He specializes in general gynecology, contraception and menopausal medicine.
Additional Positions:
Medical Director
2016 – Current
·
UF Health Women's Specialists – Emerson
Professor of Obstetrics and Gynecology
1994 – Current
·
University of Florida
Associate Chair
1994 – Current
·
UF Department of Obstetrics and Gynecology – Jacksonville
Accomplishments
30-Year Service Pin
2018
·
University of Florida College of Medicine – Jacksonville
University of Florida Research Foundation Professorship
2014
·
University of Florida
Robert C. Nuss Researcher/Scholar of the Year
2013
·
University of Florida College of Medicine – Jacksonville
Exemplary Teacher Award
2012
·
University of Florida College of Medicine – Jacksonville
Top Doctor
2012
·
U.S. News & World Report
Top Doctors
2012
·
Castle Connolly
Louis S. Russo Award for Outstanding Professionalism in Medicine
2011
·
University of Florida College of Medicine – Jacksonville
Menopause Journal Editorial Board
2010
·
North American Menopause Society
President
2010
·
Florida Obstetric and Gynecologic Society
Roy M. Pitkin Award
2010
·
American College of Obstetricians and Gynecologists
Teaching Profile
Courses Taught
2018
MDC7180 Obs and Gyn Clerkship
Board Certifications
-
Obstetrics and GynecologyAmerican Board of Obstetrics and Gynecology
Clinical Profile
Specialties
- Obstetrics and Gynecology
Areas of Interest
- Intrauterine devices (IUD)
- Menopause
Publications
Academic Articles
2025
Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks.
American journal of obstetrics and gynecology.
232(3):262-270.e1
[DOI] 10.1016/j.ajog.2024.10.054.
[PMID] 39521301.
2024
Breast cancer incidence and mortality by metabolic syndrome and obesity: The Women’s Health Initiative.
Cancer.
130(18):3147-3156
[DOI] 10.1002/cncr.35318.
[PMID] 38736319.
2024
Hormonal Medications for Genitourinary Syndrome of Menopause.
Clinical obstetrics and gynecology.
67(1):68-78
[DOI] 10.1097/GRF.0000000000000835.
[PMID] 38032827.
2024
Methods for the induction of labor: efficacy and safety.
American journal of obstetrics and gynecology.
230(3S):S669-S695
[DOI] 10.1016/j.ajog.2023.02.009.
[PMID] 38462252.
2024
Outpatient cervical ripening and labor induction with low-dose vaginal misoprostol reduces the interval to delivery: a systematic review and network meta-analysis.
American journal of obstetrics and gynecology.
230(3S):S716-S728.e61
[DOI] 10.1016/j.ajog.2022.09.043.
[PMID] 38462254.
2024
Single-balloon catheter with concomitant vaginal misoprostol is the most effective strategy for labor induction: a meta-review with network meta-analysis.
American journal of obstetrics and gynecology.
230(3S):S696-S715
[DOI] 10.1016/j.ajog.2022.01.005.
[PMID] 38462253.
2024
Water birth: a systematic review and meta-analysis of maternal and neonatal outcomes.
American journal of obstetrics and gynecology.
230(3S):S961-S979.e33
[DOI] 10.1016/j.ajog.2023.08.034.
[PMID] 38462266.
2023
Disparities in Timeliness of Endometrial Cancer Care: A Scoping Review.
Obstetrics and gynecology.
142(4):967-977
[DOI] 10.1097/AOG.0000000000005338.
[PMID] 37734095.
2023
Intrapartum amnioinfusion reduces meconium aspiration syndrome and improves neonatal outcomes in patients with meconium-stained fluid: a systematic review and meta-analysis.
American journal of obstetrics and gynecology.
228(5S):S1179-S1191.e19
[DOI] 10.1016/j.ajog.2022.07.047.
[PMID] 37164492.
2023
Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.
The Journal of clinical endocrinology and metabolism.
108(11):e1448-e1449
[DOI] 10.1210/clinem/dgad209.
[PMID] 37097747.
2023
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Circulation.
147(7):597-610
[DOI] 10.1161/CIRCULATIONAHA.122.061559.
[PMID] 36780393.
2022
Incorporating Black women’s perspectives into long-acting reversible contraception implementation.
F&S reports.
3(2 Suppl):80-90
[DOI] 10.1016/j.xfre.2022.02.005.
[PMID] 35937447.
2022
Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol/drospirenone on bleeding patterns in healthy women.
Contraception.
116:29-36
[DOI] 10.1016/j.contraception.2022.07.010.
[PMID] 35921872.
2022
Pooled efficacy results of estetrol/drospirenone combined oral contraception phase 3 trials.
Contraception.
116:37-43
[DOI] 10.1016/j.contraception.2022.07.009.
[PMID] 35921870.
2022
Reassuring data regarding the use of hormone therapy at menopause and risk of breast cancer.
Menopause (New York, N.Y.).
29(9):1001-1004
[DOI] 10.1097/GME.0000000000002057.
[PMID] 35998670.
2022
Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials.
Contraception.
116:44-50
[DOI] 10.1016/j.contraception.2022.10.004.
[PMID] 36257374.
2021
A Low 50-gram, 1-hour Glucose Challenge Test Value Predicts Neonatal Birth Weight Less than the 10th Percentile: A Systematic Review and Meta-Analysis.
American journal of perinatology.
38(8):841-847
[DOI] 10.1055/s-0039-3402749.
[PMID] 31986539.
2021
Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women’s Health Initiative.
Menopause (New York, N.Y.).
28(6):610-618
[DOI] 10.1097/GME.0000000000001753.
[PMID] 33950030.
2021
Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.
Contraception.
103(3):137-143
[DOI] 10.1016/j.contraception.2020.11.011.
[PMID] 33259782.
2021
Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results.
Contraception.
104(3):222-228
[DOI] 10.1016/j.contraception.2021.05.002.
[PMID] 34000251.
2021
Genital powder use and risk of uterine cancer: A pooled analysis of prospective studies.
International journal of cancer.
148(11):2692-2701
[DOI] 10.1002/ijc.33470.
[PMID] 33433939.
2021
Hormonal Contraception: Systemic Estrogen and Progestin Preparations.
Clinical obstetrics and gynecology.
64(4):721-738
[DOI] 10.1097/GRF.0000000000000634.
[PMID] 34668886.
2021
Maintaining cognitive function in surgically menopausal women: the importance of estrogen.
Menopause (New York, N.Y.).
28(4):349-351
[DOI] 10.1097/GME.0000000000001743.
[PMID] 33570874.
2021
Pregnancy outcomes associated with an abnormal 50-g glucose screen during pregnancy: a systematic review and Meta-analysis.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
34(24):4132-4140
[DOI] 10.1080/14767058.2019.1706473.
[PMID] 31893960.
2021
Risks of Testosterone for Postmenopausal Women.
Endocrinology and metabolism clinics of North America.
50(1):139-150
[DOI] 10.1016/j.ecl.2020.10.007.
[PMID] 33518182.
2021
Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system.
Contraception.
104(3):229-234
[DOI] 10.1016/j.contraception.2021.03.024.
[PMID] 33785318.
2021
Treatment of Women After Bilateral Salpingo-oophorectomy Performed Prior to Natural Menopause.
JAMA.
326(14):1429-1430
[DOI] 10.1001/jama.2021.3305.
[PMID] 34636868.
2020
17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
Menopause (New York, N.Y.).
27(12):1382-1387
[DOI] 10.1097/GME.0000000000001615.
[PMID] 32740481.
2020
Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.
JAMA.
323(1):49-59
[DOI] 10.1001/jama.2019.20079.
[PMID] 31910280.
2020
Best Practices for Counseling Adolescents about the Etonogestrel Implant.
Journal of pediatric and adolescent gynecology.
33(5):448-454
[DOI] 10.1016/j.jpag.2020.06.022.
[PMID] 32621879.
2020
Does umbilical cord milking increase the risk of severe intraventricular hemorrhage in extreme preterm neonates? A multitreatment comparison.
American journal of obstetrics and gynecology.
223(4):590-592
[DOI] 10.1016/j.ajog.2020.06.043.
[PMID] 32593537.
2020
Hormone therapy and sarcopenia: implications for the prevention of frailty as women age.
Menopause (New York, N.Y.).
27(5):496-497
[DOI] 10.1097/GME.0000000000001541.
[PMID] 32187132.
2020
In Reply.
Menopause (New York, N.Y.).
27(9):1097-1098
[DOI] 10.1097/GME.0000000000001625.
[PMID] 32852466.
2020
Intercepting Endometrial Cancer: Opportunities to Expand Access Using New Technology.
Cancer prevention research (Philadelphia, Pa.).
13(7):563-568
[DOI] 10.1158/1940-6207.CAPR-19-0556.
[PMID] 32047026.
2020
Serial Bone Density Measurement and Incident Fracture Risk Discrimination in Postmenopausal Women.
JAMA internal medicine.
180(9):1232-1240
[DOI] 10.1001/jamainternmed.2020.2986.
[PMID] 32730575.
2020
Surgical menopause: health implications and hormonal management.
Menopause (New York, N.Y.).
28(1):1-3
[DOI] 10.1097/GME.0000000000001680.
[PMID] 33048864.
2020
The National Academies of Science, Engineering, and Medicine (NASEM) Report on Compounded Bioidentical Hormone Therapy.
Menopause (New York, N.Y.).
27(11):1199-1201
[DOI] 10.1097/GME.0000000000001672.
[PMID] 33110032.
2020
The Women’s Health Initiative trials of menopausal hormone therapy: lessons learned.
Menopause (New York, N.Y.).
27(8):918-928
[DOI] 10.1097/GME.0000000000001553.
[PMID] 32345788.
2020
TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
Menopause (New York, N.Y.).
27(11):1236-1241
[DOI] 10.1097/GME.0000000000001602.
[PMID] 33110039.
2019
Abnormal Uterine Bleeding in Reproductive-Age Women.
JAMA.
321(21):2126-2127
[DOI] 10.1001/jama.2019.5248.
[PMID] 31070673.
2019
Associations of a Healthy Lifestyle Index With the Risks of Endometrial and Ovarian Cancer Among Women in the Women’s Health Initiative Study.
American journal of epidemiology.
188(2):261-273
[DOI] 10.1093/aje/kwy249.
[PMID] 30407487.
2019
Breast Cancer and the Obstetrician-Gynecologist: A Focus on Screening, Risk Assessment and Treatment of Survivors With Genitourinary Syndrome of Menopause.
Clinical obstetrics and gynecology.
62(4):634-643
[DOI] 10.1097/GRF.0000000000000479.
[PMID] 31259841.
2019
Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use?
Contraception.
100(4):264-268
[DOI] 10.1016/j.contraception.2019.05.017.
[PMID] 31176688.
2019
Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
Menopause (New York, N.Y.).
26(11):1259-1264
[DOI] 10.1097/GME.0000000000001394.
[PMID] 31688572.
2019
Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices.
Menopause (New York, N.Y.).
26(9):994-1001
[DOI] 10.1097/GME.0000000000001350.
[PMID] 31453961.
2019
Global Consensus Position Statement on the Use of Testosterone Therapy for Women.
The Journal of clinical endocrinology and metabolism.
104(10):4660-4666
[DOI] 10.1210/jc.2019-01603.
[PMID] 31498871.
2019
Global Consensus Position Statement on the Use of Testosterone Therapy for Women.
Climacteric : the journal of the International Menopause Society.
22(5):429-434
[DOI] 10.1080/13697137.2019.1637079.
[PMID] 31474158.
2019
Global Consensus Position Statement on the use of Testosterone Therapy for Women.
Maturitas.
128:89-93
[DOI] 10.1016/j.maturitas.2019.07.001.
[PMID] 31484631.
2019
Global Consensus Position Statement on the Use of Testosterone Therapy for Women.
The journal of sexual medicine.
16(9):1331-1337
[DOI] 10.1016/j.jsxm.2019.07.012.
[PMID] 31488288.
2019
Management of Menopause and the Role For Hormone Therapy.
Clinical obstetrics and gynecology.
62(4):677-686
[DOI] 10.1097/GRF.0000000000000487.
[PMID] 31503029.
2019
Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial.
Annals of internal medicine.
171(6):406-414
[DOI] 10.7326/M19-0274.
[PMID] 31499528.
2019
Menopause Management Knowledge in Postgraduate Family Medicine, Internal Medicine, and Obstetrics and Gynecology Residents: A Cross-Sectional Survey.
Mayo Clinic proceedings.
94(2):242-253
[DOI] 10.1016/j.mayocp.2018.08.033.
[PMID] 30711122.
2019
Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms.
Climacteric : the journal of the International Menopause Society.
22(6):610-616
[DOI] 10.1080/13697137.2019.1640197.
[PMID] 31364889.
2019
Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Menopause (New York, N.Y.).
26(5):506-512
[DOI] 10.1097/GME.0000000000001271.
[PMID] 30489424.
2019
Povidone-iodine 1% is the most effective vaginal antiseptic for preventing post-cesarean endometritis: a systematic review and network meta-analysis.
American journal of obstetrics and gynecology.
221(3):261.e1-261.e20
[DOI] 10.1016/j.ajog.2019.04.002.
[PMID] 30954518.
2019
Reproductive health care across the lifecourse of the female cancer patient.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
27(1):23-32
[DOI] 10.1007/s00520-018-4360-5.
[PMID] 30051202.
2019
Vaginal estrogen: Underprescribed treatment for an underdiagnosed condition of menopausal women.
Maturitas.
121:83-85
[DOI] 10.1016/j.maturitas.2018.08.001.
[PMID] 30098845.
2019
Women harmed by vaginal laser for treatment of GSM-the latest casualties of fear and confusion surrounding hormone therapy.
Menopause (New York, N.Y.).
26(4):338-340
[DOI] 10.1097/GME.0000000000001313.
[PMID] 30789455.
2018
A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
Obstetrics and gynecology.
132(1):161-170
[DOI] 10.1097/AOG.0000000000002645.
[PMID] 29889748.
2018
Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study.
Menopause (New York, N.Y.).
25(1):11-20
[DOI] 10.1097/GME.0000000000000956.
[PMID] 28816933.
2018
Concern about US Preventive Services Task Force recommendation on hormone therapy for the primary prevention of chronic conditions in postmenopausal women.
Menopause (New York, N.Y.).
25(5)
[DOI] 10.1097/GME.0000000000001100.
[PMID] 29658911.
2018
Contraception for midlife women: a review.
Menopause (New York, N.Y.).
25(7):817-827
[DOI] 10.1097/GME.0000000000001073.
[PMID] 29462093.
2018
Extended Use of Systemic Menopausal Hormone Therapy.
Clinical obstetrics and gynecology.
61(3):517-522
[DOI] 10.1097/GRF.0000000000000382.
[PMID] 29781874.
2018
Foreword: Managing Menopause by Combining Evidence With Clinical Judgment.
Clinical obstetrics and gynecology.
61(3):417-418
[DOI] 10.1097/GRF.0000000000000387.
[PMID] 29889666.
2018
Hormonal contraception and risk of breast cancer: a closer look.
Menopause (New York, N.Y.).
25(5):477-479
[DOI] 10.1097/GME.0000000000001101.
[PMID] 29557848.
2018
Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.
Menopause (New York, N.Y.).
26(6):622-628
[DOI] 10.1097/GME.0000000000001278.
[PMID] 30586005.
2018
Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health.
Menopause (New York, N.Y.).
25(6):596-608
[DOI] 10.1097/GME.0000000000001121.
[PMID] 29762200.
2018
Not time to abandon use of local vaginal hormone therapies.
Menopause (New York, N.Y.).
25(8):855-858
[DOI] 10.1097/GME.0000000000001142.
[PMID] 29894370.
2018
Screening mammography for average-risk women.
Menopause (New York, N.Y.).
25(3):343-345
[DOI] 10.1097/GME.0000000000001026.
[PMID] 29257034.
2018
Vasomotor symptoms and the risk of incident venous thrombosis in postmenopausal women.
Journal of thrombosis and haemostasis : JTH.
16(5):886-892
[DOI] 10.1111/jth.13993.
[PMID] 29504242.
2017
A systematic review and meta-analysis of hypocalciuria in pre-eclampsia.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
138(1):3-11
[DOI] 10.1002/ijgo.12165.
[PMID] 28369876.
2017
Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women’s Health Initiative Observational Study.
Menopause (New York, N.Y.).
24(10):1145-1153
[DOI] 10.1097/GME.0000000000000899.
[PMID] 28697036.
2017
Contraceptive Considerations for Women with Gastrointestinal Disorders.
Digestive diseases and sciences.
62(1):54-63
[DOI] 10.1007/s10620-016-4383-z.
[PMID] 27885460.
2017
Long-acting reversible contraception: an important solution to reduce unintended pregnancy.
American journal of obstetrics and gynecology.
216(5)
[DOI] 10.1016/j.ajog.2017.03.004.
[PMID] 28284931.
2017
Menopausal hormone therapy and national time trends in mortality: cautions regarding causal inference.
Menopause (New York, N.Y.).
24(8):874-876
[DOI] 10.1097/GME.0000000000000886.
[PMID] 28486245.
2017
The 2017 Hormone Therapy Position Statement of the North American Menopause Society
Menopause-the Journal of the North American Menopause Society.
24(7):728-753
[DOI] 10.1097/GME.0000000000000921.
2017
The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.
Menopause (New York, N.Y.).
24(4):360-370
[DOI] 10.1097/GME.0000000000000777.
[PMID] 27922933.
2017
The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience.
Contraception.
95(2):205-210
[DOI] 10.1016/j.contraception.2016.07.012.
[PMID] 27452317.
2017
Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance.
Menopause (New York, N.Y.).
24(12):1329-1332
[DOI] 10.1097/GME.0000000000000996.
[PMID] 29040220.
2016
An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas.
Journal of minimally invasive gynecology.
23(3):303-8
[DOI] 10.1016/j.jmig.2015.12.012.
[PMID] 26773577.
2016
Clinical trials of new treatments for menopausal conditions: paying attention to race.
Menopause (New York, N.Y.).
23(6):589-90
[DOI] 10.1097/GME.0000000000000637.
[PMID] 27070806.
2016
Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.
21(2):106-15
[DOI] 10.3109/13625187.2015.1107894.
[PMID] 26572318.
2016
In Reply.
Obstetrics and gynecology.
127(5):966-967
[DOI] 10.1097/AOG.0000000000001416.
[PMID] 27101114.
2016
Menopause Management–Getting Clinical Care Back on Track.
The New England journal of medicine.
374(9):803-6
[DOI] 10.1056/NEJMp1514242.
[PMID] 26962899.
2016
Single abnormal value on 3-hour oral glucose tolerance test during pregnancy is associated with adverse maternal and neonatal outcomes: a systematic review and metaanalysis.
American journal of obstetrics and gynecology.
215(3):287-97
[DOI] 10.1016/j.ajog.2016.04.040.
[PMID] 27133007.
2016
Stopping systemic menopausal hormone therapy: Why, when and how.
Maturitas.
89:3-4
[DOI] 10.1016/j.maturitas.2016.03.020.
[PMID] 27180152.
2016
U.S. Food and Drug Administration’s Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women?
Obstetrics and gynecology.
127(1):18-22
[DOI] 10.1097/AOG.0000000000001157.
[PMID] 26646134.
2016
Use of systemic hormone therapy in BRCA mutation carriers.
Menopause (New York, N.Y.).
23(9):1026-7
[DOI] 10.1097/GME.0000000000000724.
[PMID] 27504919.
2015
Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society.
Menopause (New York, N.Y.).
22(3):247-53
[DOI] 10.1097/GME.0000000000000373.
[PMID] 25314150.
2015
Antenatal exposure to indomethacin increases the risk of severe intraventricular hemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis.
American journal of obstetrics and gynecology.
212(4):505.e1-13
[DOI] 10.1016/j.ajog.2014.10.1091.
[PMID] 25448524.
2015
Balancing the efficacy and safety of misoprostol: a meta-analysis comparing 25 versus 50 micrograms of intravaginal misoprostol for the induction of labour.
BJOG : an international journal of obstetrics and gynaecology.
122(4):468-76
[DOI] 10.1111/1471-0528.12935.
[PMID] 24989790.
2015
Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women’s Health Initiative Randomized Clinical Trials.
JAMA oncology.
1(3):296-305
[DOI] 10.1001/jamaoncol.2015.0494.
[PMID] 26181174.
2015
Compounded bioidentical hormone therapy: time for a reality check?
Menopause (New York, N.Y.).
22(9):919-20
[DOI] 10.1097/GME.0000000000000484.
[PMID] 26035149.
2015
Does Cervical Ripening With Foley Catheters Increase Infectious Morbidity? a Systematic Review With Meta-Analysis
Obstetrics and Gynecology.
125(1)
2015
Evaluation of a Transcervical Foley Catheter as a Source of Infection: A Systematic Review and Meta-analysis.
Obstetrics and gynecology.
126(3):539-551
[DOI] 10.1097/AOG.0000000000001002.
[PMID] 26244535.
2015
Failure to treat menopausal symptoms: a disconnect between clinical practice and scientific data.
Menopause (New York, N.Y.).
22(7):687-8
[DOI] 10.1097/GME.0000000000000457.
[PMID] 25850357.
2015
Management of Menopausal Symptoms.
Obstetrics and gynecology.
126(4):859-876
[DOI] 10.1097/AOG.0000000000001058.
[PMID] 26348174.
2015
NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older.
Menopause (New York, N.Y.).
22(7):685-6
[DOI] 10.1097/GME.0000000000000491.
[PMID] 26035151.
2015
New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 study.
Contraception.
91(3):211-6
[DOI] 10.1016/j.contraception.2014.11.013.
[PMID] 25586864.
2015
Ovarian cysts: presence and persistence with use of a 13.5mg levonorgestrel-releasing intrauterine system.
Contraception.
91(5):412-7
[DOI] 10.1016/j.contraception.2015.01.021.
[PMID] 25661510.
2015
Reply: To PMID 25448524.
American journal of obstetrics and gynecology.
213(6)
[DOI] 10.1016/j.ajog.2015.08.023.
[PMID] 26283456.
2015
Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2).
Cancer causes & control : CCC.
26(2):287-296
[DOI] 10.1007/s10552-014-0510-3.
[PMID] 25534916.
2015
Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.
American journal of obstetrics and gynecology.
212(3):318.e1-8
[DOI] 10.1016/j.ajog.2014.09.014.
[PMID] 25220709.
2015
Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.
Contraception.
91(3):204-10
[DOI] 10.1016/j.contraception.2014.11.011.
[PMID] 25582984.
2014
Cervical and vaginal flora specimens are highly concordant with respect to bacterial vaginosis-associated organisms and commensal Lactobacillus species in women of reproductive age.
Journal of clinical microbiology.
52(8):3078-81
[DOI] 10.1128/JCM.00795-14.
[PMID] 24899020.
2014
Comment on ‘practical advice for avoidance of pain associated with insertion of intrauterine contraceptives’: authors’ response.
The journal of family planning and reproductive health care.
40(2):152-3
[DOI] 10.1136/jfprhc-2014-100874.
[PMID] 24648536.
2014
Comment on ‘Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives’: authors’ response.
The journal of family planning and reproductive health care.
40(3)
[DOI] 10.1136/jfprhc-2014-100925.
[PMID] 24939488.
2014
Comment On `Practical Advice for Avoidance of Pain Associated With Insertion of Intrauterine Contraceptives’: Authors’ Response
Journal of Family Planning and Reproductive Health Care.
40(2):152-U82
[DOI] 10.1136/jfprhc-2013-100848.
[PMID] 24648535.
2014
Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.
Menopause (New York, N.Y.).
21(10):1082-90
[DOI] 10.1097/GME.0000000000000210.
[PMID] 24552977.
2014
Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
Contraception.
89(4):299-306
[DOI] 10.1016/j.contraception.2014.01.013.
[PMID] 24576794.
2014
Extended duration use of menopausal hormone therapy.
Menopause (New York, N.Y.).
21(6):679-81
[DOI] 10.1097/GME.0000000000000175.
[PMID] 24398408.
2014
Global fee prohibits postpartum provision of the most effective reversible contraceptives.
Contraception.
90(5):466-7
[DOI] 10.1016/j.contraception.2014.08.005.
[PMID] 25212061.
2014
Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women’s Health Initiative Observational Study.
Menopause (New York, N.Y.).
21(3):260-6
[DOI] 10.1097/GME.0b013e31829a64f9.
[PMID] 24045672.
2014
In reply.
Obstetrics and gynecology.
123(5):1107-1108
[DOI] 10.1097/AOG.0000000000000248.
[PMID] 24785870.
2014
Injectable contraception: issues and opportunities.
Contraception.
89(5):331-4
[DOI] 10.1016/j.contraception.2014.03.014.
[PMID] 24767245.
2014
Long-Term Issues in Hormone Therapy Management
Menopause-the Journal of the North American Menopause Society.
21(12)
2014
Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial.
BJOG : an international journal of obstetrics and gynaecology.
121(6):700-5; discussion 705
[DOI] 10.1111/1471-0528.12598.
[PMID] 24533510.
2014
Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
Obstetrics and gynecology.
123(2 Pt 1):295-303
[DOI] 10.1097/AOG.0000000000000095.
[PMID] 24402597.
2014
Paroxetine 7.5 Mg Reduces Daily Frequency and Severity of Vasomotor Symptoms (Vms) Associated With Menopause: Results From 2 Multicenter, Randomized, Double-Blind, Controlled Phase 3 Studies
Journal of Womens Health.
23(4)
2014
Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives.
The journal of family planning and reproductive health care.
40(1):54-60
[DOI] 10.1136/jfprhc-2013-100636.
[PMID] 24076534.
2014
The Association Between Vasomotor Symptoms and Hemostatic Factors in Postmenopausal Women
Menopause-the Journal of the North American Menopause Society.
21(12):1332-1333
2014
The short-term prediction of preterm birth: a systematic review and diagnostic metaanalysis.
American journal of obstetrics and gynecology.
210(1):54.e1-54.e10
[DOI] 10.1016/j.ajog.2013.09.004.
[PMID] 24021995.
2014
Why the product labeling for low-dose vaginal estrogen should be changed.
Menopause (New York, N.Y.).
21(9):911-6
[DOI] 10.1097/GME.0000000000000316.
[PMID] 25140698.
2013
Bleeding Profile of a Novel Ascending-Dose, Extended-Regimen Ethinyl Estradiol/Levonorgestrel Combination Oral Contraceptive (Oc)
Contraception.
88:311-312
2013
Comment on journal review of ‘Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture’.
The journal of family planning and reproductive health care.
39(4)
[DOI] 10.1136/jfprhc-2013-100759.
[PMID] 24062508.
2013
Contraception in women over 40 years of age.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
185(7):565-73
[DOI] 10.1503/cmaj.121280.
[PMID] 23460635.
2013
Hormonal and intrauterine contraception for women aged 40 years and older.
Women's health (London, England).
9(5):421-4
[DOI] 10.2217/whe.13.38.
[PMID] 24007246.
2013
Impact On Body Weight and Sexual Function During Treatment of Vasomotor Symptoms (Vms) Due To Menopause With Low-Dose Mesylate Salt of Paroxetine (Ldmp)
Menopause-the Journal of the North American Menopause Society.
20(12)
2013
Impact On Body Weight and Sexual Function During Treatment of Vasomotor Symptoms (Vms) Due To Menopause With Low-Dose Mesylate Salt of Paroxetine (Ldmp)
Menopause-the Journal of the North American Menopause Society.
20(12)
2013
Is Uterine Leiomyomata Associated With Postmenopausal Bleeding? a Retrospective Review
Menopause-the Journal of the North American Menopause Society.
20(12)
2013
Lessons learned from the Women’s Health Initiative trials of menopausal hormone therapy.
Obstetrics and gynecology.
121(1):172-6
[PMID] 23262943.
2013
Low-Dose Mesylate Salt of Paroxetine (Ldmp) Reduced Daily Frequency and Severity of Vasomotor Symptoms (Vms) Due To Menopause
Menopause-the Journal of the North American Menopause Society.
20(12):1340-1341
2013
Low-Dose Mesylate Salt of Paroxetine (Ldmp) Reduced Daily Frequency of Moderate Vasomotor Symptoms (Vms) and Severe Vms Due To Menopause
Menopause-the Journal of the North American Menopause Society.
20(12)
2013
Low-Dose Mesylate Salt of Paroxetine (Ldmp) Reduced Daily Frequency of Moderate Vasomotor Symptoms (Vms) and Severe Vms Due To Menopause
Menopause-the Journal of the North American Menopause Society.
20(12)
2013
Low-Dose Mesylate Salt of Paroxetine (Ldmp) Reduced Patient Burden of Menopausal Vasomotor Symptoms
Menopause-the Journal of the North American Menopause Society.
20(12)
2013
Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.
Menopause (New York, N.Y.).
20(10):1027-35
[DOI] 10.1097/GME.0b013e3182a66aa7.
[PMID] 24045678.
2013
Management of pain associated with the insertion of intrauterine contraceptives.
Human reproduction update.
19(4):419-27
[DOI] 10.1093/humupd/dmt022.
[PMID] 23670222.
2013
Should new-onset arthralgia be considered a menopausal symptom?
Menopause (New York, N.Y.).
20(6):591-3
[DOI] 10.1097/GME.0b013e31828a6a3d.
[PMID] 23549444.
2013
Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.
18(3):143-7
[DOI] 10.3109/13625187.2013.792637.
[PMID] 23578274.
2013
Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
The journal of family planning and reproductive health care.
39(3):156-9
[DOI] 10.1136/jfprhc-2013-100624.
[PMID] 23585363.
2013
The levonorgestrel intrauterine system: effective non-surgical treatment for heavy menstrual bleeding.
Evidence-based medicine.
18(6)
[DOI] 10.1136/eb-2013-101275.
[PMID] 23635841.
2013
The protein-to-creatinine ratio for the prediction of significant proteinuria in patients at risk for preeclampsia: a meta-analysis.
Annals of clinical and laboratory science.
43(2):211-20
[PMID] 23694798.
2013
Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture.
Obstetrics and gynecology.
121(3):593-600
[DOI] 10.1097/AOG.0b013e318283d1a1.
[PMID] 23635623.
2012
Disparity in menopausal hormone therapy use between women obstetrician gynecologists and women overall: are obstetrician gynecologists underserving their patients?
Menopause (New York, N.Y.).
19(10):1070-1
[PMID] 22929036.
2012
Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial.
Obstetrics and gynecology.
119(5):989-99
[DOI] 10.1097/AOG.0b013e318250c3a0.
[PMID] 22525910.
2012
Increased Compliance Independent of Patient Demographics With a Low-Dose Combination Contraceptive Patch (Ag200-15) Compared With a Low-Dose Combination Oral Contraceptive in a Phase 3 Clinical Trial
Contraception.
86
2012
Increased Compliance Independent of Patient Demographics With a Low-Dose Combination Contraceptive Patch (Ag200-15) Compared With a Low-Dose Combination Oral Contraceptive in a Phase 3 Clinical Trial
Contraception.
86
2012
Increased Compliance With a Low-Dose Combination Contraceptive Patch (Ag200-15) Compared With a Low-Dose Combination Oral Contraceptive (Coc) in a Phase 3 Clinical Trial
Contraception.
86
2012
Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels.
Contraception.
86(5):452-7
[DOI] 10.1016/j.contraception.2012.07.018.
[PMID] 22959906.
2012
Study had insufficient power to investigate safety.
BMJ (Clinical research ed.).
345
[DOI] 10.1136/bmj.e8146.
[PMID] 23208257.
2012
The 2010 North American Menopause Society Position Statement On Hormone Therapy Goes Beyond the Available Evidence Response
Menopause-the Journal of the North American Menopause Society.
19(7):836-837
[DOI] 10.1097/gme.0b013e31825b32ea.
2012
The Levonorgestrel-Releasing Intrauterine System in Heavy Menstrual Bleeding a Benefit-Risk Review
.
72:193-215
2012
The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review.
Drugs.
72(2):193-215
[DOI] 10.2165/11598960-000000000-00000.
[PMID] 22268392.
2012
Transdermal and vaginal estradiol for the treatment of menopausal symptoms: the nuts and bolts.
Menopause (New York, N.Y.).
19(6):602-3
[DOI] 10.1097/gme.0b013e31824c8a5a.
[PMID] 22549171.
2011
Incidental diagnosis of appendiceal mucocele with vaginal ultrasonography and computed tomography.
Obstetrics and gynecology.
117(2 Pt 2):479-481
[DOI] 10.1097/AOG.0b013e318203ea37.
[PMID] 21252796.
2011
Removing the black box warning for depot medroxyprogesterone acetate.
Contraception.
84(3):212-3
[DOI] 10.1016/j.contraception.2011.01.009.
[PMID] 21843682.
2011
Update on hormonal contraception and bone density.
Reviews in endocrine & metabolic disorders.
12(2):93-106
[DOI] 10.1007/s11154-011-9180-6.
[PMID] 21559817.
2010
Cycle Control With a 21-Day Compared With a 24-Day Oral Contraceptive Pill: a Randomized Controlled Trial Reply
Obstetrics and Gynecology.
115(4):867-868
[DOI] 10.1097/AOG.0b013e3181d7047e.
2010
Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
Women's health (London, England).
6(3):339-42
[DOI] 10.2217/whe.10.17.
[PMID] 20426597.
2010
Levonorgestrel-Releasing Intrauterine System Or Medroxyprogesterone for Heavy Menstrual Bleeding: a Randomized Controlled Trial Reply
Obstetrics and Gynecology.
116(6)
[DOI] 10.1097/AOG.0b013e3181ff7331.
2010
Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial.
Obstetrics and gynecology.
116(3):625-632
[DOI] 10.1097/AOG.0b013e3181ec622b.
[PMID] 20733445.
2010
The Oncogenic Potential of Endometrial Polyps: a Systematic Review and Meta-Analysis
Menopause-the Journal of the North American Menopause Society.
17
2010
The oncogenic potential of endometrial polyps: a systematic review and meta-analysis.
Obstetrics and gynecology.
116(5):1197-205
[DOI] 10.1097/AOG.0b013e3181f74864.
[PMID] 20966706.
2009
Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.
Contraception.
79(5):350-5
[DOI] 10.1016/j.contraception.2008.11.011.
[PMID] 19341846.
2009
An evidence-based approach to postpartum use of depot medroxyprogesterone acetate in breastfeeding women.
Contraception.
80(1):4-6
[DOI] 10.1016/j.contraception.2008.12.014.
[PMID] 19501209.
2009
Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial.
Obstetrics and gynecology.
114(6):1205-1212
[DOI] 10.1097/AOG.0b013e3181beab47.
[PMID] 19935020.
2009
Depo-Provera and skeletal health: reviewing the evidence; developing and disseminating a consensus.
Contraception.
79(3):165-6
[DOI] 10.1016/j.contraception.2008.06.017.
[PMID] 19185667.
2009
Diagnostic accuracy of transvaginal sonography for the diagnosis of adenomyosis: systematic review and metaanalysis.
American journal of obstetrics and gynecology.
201(1):107.e1-6
[DOI] 10.1016/j.ajog.2009.03.021.
[PMID] 19398089.
2009
Effective herbal treatment of vasomotor symptoms–are we any closer?
Menopause (New York, N.Y.).
16(3):428-9
[DOI] 10.1097/gme.0b013e31819774e4.
[PMID] 19169160.
2009
Ethics and referral for abortion.
American journal of obstetrics and gynecology.
200(6):e9; author reply e9-10
[DOI] 10.1016/j.ajog.2008.12.017.
[PMID] 19286151.
2009
Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients: a meta-analysis.
Obstetrics and gynecology.
114(3):631-640
[DOI] 10.1097/AOG.0b013e3181b47217.
[PMID] 19701045.
2009
Levonorgestrel Intrauterine System and Medroxyprogesterone Acetate for Treatment of Heavy Menstrual Bleeding
Contraception.
80
2009
Levonorgestrel-Releasing Intrauterine System and Endometrial Ablation in Heavy Menstrual Bleeding a Systematic Review and Meta-Analysis
Obstetrics and Gynecology.
113:1104-1116
2009
Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis.
Obstetrics and gynecology.
113(5):1104-1116
[DOI] 10.1097/AOG.0b013e3181a1d3ce.
[PMID] 19384127.
2009
Postmenopausal osteoporosis: fracture risk and prevention.
The Journal of family practice.
58(11 Suppl Postmenopausal):S1-6
[PMID] 19891943.
2009
Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials.
Fertility and sterility.
91(5):1646-53
[DOI] 10.1016/j.fertnstert.2008.02.140.
[PMID] 18423453.
2009
Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
Contraception.
80(1):7-17
[DOI] 10.1016/j.contraception.2009.02.005.
[PMID] 19501210.
2009
The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health.
Contraception.
79(3):167-77
[DOI] 10.1016/j.contraception.2008.10.016.
[PMID] 19185668.
2009
Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy.
Menopause (New York, N.Y.).
16(4):735-41
[DOI] 10.1097/gme.0b013e318199e734.
[PMID] 19252451.
2009
Use of hormonal contraception in adolescents: skeletal health issues.
Current opinion in obstetrics & gynecology.
21(5):396-401
[DOI] 10.1097/GCO.0b013e32832c9cc6.
[PMID] 19491681.
2008
Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.
Contraception.
77(2):67-76
[DOI] 10.1016/j.contraception.2007.10.005.
[PMID] 18226668.
2008
Clinical practice. Hormonal contraception in women of older reproductive age.
The New England journal of medicine.
358(12):1262-70
[DOI] 10.1056/NEJMcp0708481.
[PMID] 18354104.
2008
Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians.
Contraception.
78(5):370-6
[DOI] 10.1016/j.contraception.2008.07.022.
[PMID] 18929733.
2008
Depot Medroxyprogesterone Acetate and Skeletal Health: a Survey of Florida Ob/Gyn Physicians
Contraception.
78(2)
[DOI] 10.1016/j.contraception.2008.04.032.
2008
Do mechanical methods of cervical ripening increase infectious morbidity? A systematic review.
American journal of obstetrics and gynecology.
199(2):177-87; discussion 187
[DOI] 10.1016/j.ajog.2008.05.005.
[PMID] 18674661.
2008
Metaanalysis of Diagnostic and Prognostic Studies: the Challenge Continues – Reply
American Journal of Obstetrics and Gynecology.
199(1):E16-E17
[DOI] 10.1016/j.ajog.2008.02.040.
2007
Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata.
Menopause (New York, N.Y.).
14(5):941-3
[PMID] 17667148.
2007
Cervical length and the risk of spontaneous labor at term.
Journal of perinatology : official journal of the California Perinatal Association.
27(12):749-53
[PMID] 17762846.
2007
Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception.
Contraception.
75(1):4-10
[PMID] 17161116.
2007
Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.
Obstetrics and gynecology.
110(3):577-86
[PMID] 17766603.
2007
Long-acting contraceptives in adolescents.
Current opinion in obstetrics & gynecology.
19(5):453-60
[PMID] 17885461.
2007
Long-acting hormonal contraceptives–indispensable in preventing teen pregnancy.
The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
40(1):1-3
[PMID] 17185200.
2007
Pharmacy access to emergency hormonal contraception in Jacksonville, FL: a secret shopper survey.
Contraception.
75(2):126-30
[PMID] 17241842.
2007
Progestin-releasing intrauterine systems and leiomyoma.
Contraception.
75(6 Suppl):S130-3
[PMID] 17531604.
2007
Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials.
Contraception.
75(1):11-5
[PMID] 17161117.
2007
Sonographic cervical assessment to predict the success of labor induction: a systematic review with metaanalysis.
American journal of obstetrics and gynecology.
197(2):186-92
[PMID] 17689645.
2007
Use of the levonorgestrel-IUD in the treatment of menorrhagia: improving patient outcomes while reducing the need for surgical management.
Managed care interface.
20(3):47-50
[PMID] 17458481.
2006
Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.
Contraception.
74(2):90-9
[PMID] 16860045.
2006
Depot medroxyprogesterone acetate and bone mineral density in adolescents–the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
39(2):296-301
[PMID] 16857545.
2006
Hormone therapy and breast cancer risk: trumping fear with facts.
Menopause (New York, N.Y.).
13(2):160-3
[PMID] 16645526.
2005
Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis.
Obstetrics and gynecology.
106(1):173-9
[PMID] 15994634.
2005
Beyond the pill: new data and options in hormonal and intrauterine contraception.
American journal of obstetrics and gynecology.
192(4):998-1004
[PMID] 15846172.
2005
Contraceptive equity and access in the United States: a 2005 update.
Contraception.
71(5):317-8
[PMID] 15854629.
2005
Depo-Provera’s black box: time to reconsider?
Contraception.
72(3):165-7
[PMID] 16102548.
2005
Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial.
Obstetrics and gynecology.
105(6):1389-96
[PMID] 15932834.
2005
Maternal death caused by midgut volvulus after bariatric surgery.
American journal of obstetrics and gynecology.
193(5):1748-9
[PMID] 16260222.
2005
Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials.
Obstetrics and gynecology.
105(2):273-9
[PMID] 15684151.
2005
Sublingual misoprostol for labor induction: a randomized clinical trial.
Obstetrics and gynecology.
105(2):365-71
[PMID] 15684166.
2004
Contraceptive efficacy and safety of DMPA-SC.
Contraception.
70(4):269-75
[PMID] 15451329.
2004
Enhancing oral contraceptive success: the potential of new formulations.
American journal of obstetrics and gynecology.
190(4 Suppl):S23-9
[PMID] 15105795.
2004
Randomized trial to compare perioperative outcomes of Filshie clip vs. Pomeroy technique for postpartum and intraoperative cesarean tubal sterilization: a pilot study.
Contraception.
69(4):267-70
[PMID] 15033399.
2004
Women’s and providers’ attitudes toward menstrual suppression with extended use of oral contraceptives.
Contraception.
70(5):359-63
[PMID] 15504373.
2003
Clinical characteristics of patients with an abnormal clomiphene citrate challenge test.
American journal of obstetrics and gynecology.
189(2):348-52; discussion 352
[PMID] 14520190.
2003
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial.
JAMA.
290(13):1739-48
[PMID] 14519708.
2003
Human chorionic gonadotropin in cervicovaginal secretions as a predictor of preterm delivery.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
83(2):151-7
[PMID] 14550589.
2003
Labor induction versus expectant management for postterm pregnancies: a systematic review with meta-analysis.
Obstetrics and gynecology.
101(6):1312-8
[PMID] 12798542.
2003
Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance.
Circulation.
107(9):e67-8; author reply e67
[PMID] 12628963.
2003
Misoprostol use during the third stage of labor.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
82(2):143-52
[PMID] 12873774.
2002
Clinical manifestations of rotavirus infection in the neonatal intensive care unit.
The Pediatric infectious disease journal.
21(12):1099-105
[PMID] 12488657.
2002
Current concepts regarding use of DMPA.
The Journal of reproductive medicine.
47(9 Suppl):785-9
[PMID] 12380407.
2002
Expectant management versus labor induction for suspected fetal macrosomia: a systematic review.
Obstetrics and gynecology.
100(5 Pt 1):997-1002
[PMID] 12423867.
2002
Gynecologic problems of the perimenopause: evaluation and treatment.
Obstetrics and gynecology clinics of North America.
29(3):455-73
[PMID] 12353668.
2002
Hormone replacement therapy: where do we go now?
The breast journal.
8(6):329-31
[PMID] 12390354.
2002
Labor induction with 25 microg versus 50 microg intravaginal misoprostol: a systematic review.
Obstetrics and gynecology.
99(1):145-51
[PMID] 11777525.
2002
Noncontraceptive health benefits of oral contraceptives.
Reviews in endocrine & metabolic disorders.
3(3):277-83
[PMID] 12215722.
2002
The effect of tablet moistening on labor induction with intravaginal misoprostol: a randomized trial.
Obstetrics and gynecology.
99(6):1080-4
[PMID] 12052603.
2002
Use of combination hormone replacement therapy in light of recent data from the Women’s Health Initiative.
Medscape women's health.
7(4)
[PMID] 12466740.
2001
Adjunctive intravaginal metronidazole for the prevention of postcesarean endometritis: a randomized controlled trial.
Obstetrics and gynecology.
98(5 Pt 1):745-50
[PMID] 11704163.
2001
Current options for injectable contraception in the United States.
Seminars in reproductive medicine.
19(4):331-7
[PMID] 11727175.
2001
Injectable long-acting contraceptives.
Clinical obstetrics and gynecology.
44(1):73-91
[PMID] 11219248.
2001
Lunelle monthly injectable contraceptive. An effective, safe, and convenient new birth control option.
Archives of gynecology and obstetrics.
265(3):119-23
[PMID] 11561738.
2001
Oral contraceptive use in perimenopause.
American journal of obstetrics and gynecology.
185(2 Suppl):S32-7
[PMID] 11521120.
2001
Outpatient cervical ripening with intravaginal misoprostol.
Obstetrics and gynecology.
97(2):325-6
[PMID] 11271511.
2001
Route of breech delivery and maternal and neonatal outcomes.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
73(1):7-14
[PMID] 11336715.
2001
The hormone continuum: accrual of women’s health benefits.
International journal of fertility and women's medicine.
46(2):60-72
[PMID] 11374657.
2000
Bleeding patterns of women using Lunelle monthly contraceptive injections (medroxyprogesterone acetate and estradiol cypionate injectable suspension) compared with those of women using Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol triphasic) or other oral contraceptives.
Contraception.
62(6):289-95
[PMID] 11239615.
2000
Cervical ripening and labor induction after previous cesarean delivery.
Clinical obstetrics and gynecology.
43(3):513-23
[PMID] 10949755.
2000
Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial.
Contraception.
61(5):295-302
[PMID] 10906499.
2000
Injectable contraception. New and existing options.
Obstetrics and gynecology clinics of North America.
27(4):741-80
[PMID] 11091987.
2000
Menstruation: choosing whether…and when.
Contraception.
62(6):277-84
[PMID] 11239613.
2000
Misoprostol for cervical ripening and labor induction: a systematic review of the literature.
Clinical obstetrics and gynecology.
43(3):475-88
[PMID] 10949752.
2000
Perinatal morbidity associated with misoprostol-induced labor.
American journal of obstetrics and gynecology.
182(3):749-50
[PMID] 10739550.
2000
Prophylactic amnioinfusion for intrapartum oligohydramnios: a meta-analysis of randomized controlled trials.
Obstetrics and gynecology.
96(5 Pt 2):861-6
[PMID] 11094242.
2000
The effect of obstetric resident gender on forceps delivery rate.
American journal of obstetrics and gynecology.
182(5):1050-1
[PMID] 10819824.
2000
Uterine rupture associated with the use of prostaglandin E1 in patients with previous cesarean delivery.
American journal of obstetrics and gynecology.
182(4):990-1
[PMID] 10764490.
1999
Cervical ripening and labor induction with a controlled-release dinoprostone vaginal insert: a meta-analysis.
Obstetrics and gynecology.
94(5 Pt 2):878-83
[PMID] 10546777.
1999
Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group.
Contraception.
60(4):179-87
[PMID] 10640164.
1999
Does smoking affect efficacy of the pill? Ask the experts.
Contraceptive technology update.
20(12):143-4
[PMID] 12295560.
1999
Efficacy of maintenance therapy after acute tocolysis: a meta-analysis.
American journal of obstetrics and gynecology.
181(2):484-90
[PMID] 10454704.
1999
Long-acting hormonal contraception: assessing impact on bone density, weight, and mood.
International journal of fertility and women's medicine.
44(2):110-7
[PMID] 10338269.
1999
Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): a contraceptive method for women in the US and worldwide.
Contraception.
60(4):177-8
[PMID] 10640163.
1999
Oral contraceptive health benefits: perception versus reality.
Contraception.
59(1 Suppl):29S-33S
[PMID] 10342094.
1998
Cesarean scar pregnancy: imaging and treatment with conservative surgery.
Obstetrics and gynecology.
91(5 Pt 2):838-40
[PMID] 9572183.
1998
Devices for endometrial sampling. A comparison.
The Journal of reproductive medicine.
43(3):180-4
[PMID] 9564641.
1998
Frequent urination and Depo-Provera. Ask the experts.
Contraceptive technology update.
19(12):160-1
[PMID] 12321808.
1998
Infertility. A clinical guide for the internist.
The Medical clinics of North America.
82(2):271-95
[PMID] 9531926.
1998
Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
International journal of fertility and women's medicine.
43(2):73-83
[PMID] 9609206.
1998
Labor induction with prostaglandin E1 misoprostol compared with dinoprostone vaginal insert: a randomized trial.
Obstetrics and gynecology.
91(3):401-5
[PMID] 9491868.
1998
Oral contraceptive estrogen dose considerations.
Contraception.
58(3 Suppl):15S-21S; quiz 66S
[PMID] 9807688.
1997
Contraception for the adolescent patient.
International journal of fertility and women's medicine.
42(1):30-8
[PMID] 9113833.
1997
Estrogen component of OCs.
Dialogues in contraception.
5(4):1-6
[PMID] 12293158.
1997
Labor induction with intravaginal misoprostol in term premature rupture of membranes: a randomized study.
Obstetrics and gynecology.
89(6):909-12
[PMID] 9170463.
1997
Misoprostol for cervical ripening and labor induction: a meta-analysis.
Obstetrics and gynecology.
89(4):633-42
[PMID] 9083326.
1997
Oral administration of misoprostol for labor induction: a randomized controlled trial.
Obstetrics and gynecology.
90(1):153-4
[PMID] 9207832.
1997
Randomized trial of two doses of the prostaglandin E1 analog misoprostol for labor induction.
American journal of obstetrics and gynecology.
177(2):364-9; discussion 369
[PMID] 9290452.
1997
Reappearance of the intrauterine device: a ‘user-friendly’ contraceptive.
International journal of fertility and women's medicine.
42(2):120-7
[PMID] 9160223.
1997
The role of androgens in menopausal hormonal replacement.
Endocrinology and metabolism clinics of North America.
26(2):391-7
[PMID] 9193891.
1996
Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
The Journal of reproductive medicine.
41(5 Suppl):419-27
[PMID] 8725705.
1996
Long-acting contraceptive options.
International journal of fertility and menopausal studies.
41(2):69-76
[PMID] 8829701.
1996
Randomized trial of oxytocin alone and with propranolol in the management of dysfunctional labor.
Obstetrics and gynecology.
88(4 Pt 1):517-20
[PMID] 8841209.
1995
A trial of labor complicated by uterine rupture following amnioinfusion.
Southern medical journal.
88(8):847-8
[PMID] 7631213.
1995
Calcium supplementation in mild preeclampsia remote from term: a randomized double-blind clinical trial.
Obstetrics and gynecology.
85(6):915-8
[PMID] 7770260.
1995
Contraception. A clinical review for the internist.
The Medical clinics of North America.
79(6):1377-409
[PMID] 7475496.
1995
Labor induction in patients with previous cesarean section.
American journal of perinatology.
12(6):450-4
[PMID] 8579661.
1995
Preinduction cervical ripening with commercially available prostaglandin E2 gel: a randomized, double-blind comparison with a hospital-compounded preparation.
American journal of obstetrics and gynecology.
173(4):1079-84
[PMID] 7485297.
1995
Pyelonephritis in pregnancy: once-a-day ceftriaxone versus multiple doses of cefazolin. A randomized, double-blind trial.
American journal of obstetrics and gynecology.
172(1 Pt 1):129-33
[PMID] 7847521.
1994
Cesarean section rates in teaching hospitals: a national survey.
Birth (Berkeley, Calif.).
21(4):194-6
[PMID] 7857465.
1994
Intravaginal misoprostol versus dinoprostone as cervical ripening and labor-inducing agents.
Obstetrics and gynecology.
83(5 Pt 1):799-801
[PMID] 8164948.
1994
Long-acting injectable contraception with depot medroxyprogesterone acetate.
American journal of obstetrics and gynecology.
170(5 Pt 2):1543-9
[PMID] 8178904.
1994
Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin II-sensitive patients.
Obstetrics and gynecology.
84(3):349-53
[PMID] 8058229.
1994
Resident research in obstetrics and gynecology.
The Journal of reproductive medicine.
39(8):635-8
[PMID] 7996529.
1993
ARHP launches Depo-Provera education program.
Health and sexuality.
3(3)
[PMID] 12286568.
1993
Combined oral contraception with desogestrel/ethinyl estradiol: tolerability profile.
American journal of obstetrics and gynecology.
168(3 Pt 2):1028-33
[PMID] 8447356.
1993
Injectable contraception with depot medroxyprogesterone acetate. Current status.
Drugs.
45(6):857-865
[DOI] 10.2165/00003495-199345060-00001.
[PMID] 7691495.
1993
Labor induction with the prostaglandin E1 methyl analogue misoprostol versus oxytocin: a randomized trial.
Obstetrics and gynecology.
81(3):332-6
[PMID] 8437780.
1992
Detection of cervical Chlamydia trachomatis and Neisseria gonorrhoeae with deoxyribonucleic acid probe assays in obstetric patients.
American journal of obstetrics and gynecology.
167(3):588-91
[PMID] 1530008.
1992
Hygroscopic cervical dilators and prostaglandin E2 gel for preinduction cervical ripening. A randomized, prospective comparison.
The Journal of reproductive medicine.
37(4):355-9
[PMID] 1593561.
1992
Injectable contraception: the USA perspective.
IPPF medical bulletin.
26(6):1-3
[PMID] 12346920.
1992
Oral contraceptives and gynecologic cancer: an update for the 1990s.
American journal of obstetrics and gynecology.
167(4 Pt 2):1171-6
[PMID] 1415442.
1991
Calcium excretion in preeclampsia.
Obstetrics and gynecology.
77(4):510-3
[PMID] 2002971.
1990
Pseudotumor cerebri following eclampsia.
European neurology.
30(1):6-8
[PMID] 2298229.
1990
Reducing cesarean sections at a teaching hospital.
American journal of obstetrics and gynecology.
163(3):1081-7; discussion 1087
[PMID] 2403133.
1989
Injectable contraception.
Clinical obstetrics and gynecology.
32(2):356-68
[PMID] 2525977.
1988
Comparison of endometrial biopsy with the endometrial Pipelle and Vabra aspirator.
The Journal of reproductive medicine.
33(5):427-31
[PMID] 3385697.
1988
Successful pregnancy after previous conservative treatment of an advanced cervical pregnancy.
Obstetrics and gynecology.
71(6 Pt 2):1023-5
[PMID] 3287250.
1986
Maternal mortality in women aged 35 years or older: United States.
JAMA.
255(1):53-7
[PMID] 3940305.
1986
Mental retardation: a controversial indication for hysterectomy.
Obstetrics and gynecology.
68(3):436-8
[PMID] 3737068.
1985
Abortions that fail.
Obstetrics and gynecology.
66(4):533-7
[PMID] 4047543.
1985
Causes of maternal mortality in the United States.
Obstetrics and gynecology.
65(5):605-12
[PMID] 3982738.
1984
Maternal deaths in the United States by size of hospital.
Obstetrics and gynecology.
64(3):311-4
[PMID] 6462559.
1984
Maternal mortality surveillance, 1974-1978.
MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.
33(1):5SS-8SS
[PMID] 6433176.
1984
Outcome of out-of-hospital births should not be measured by birth weight.
Public health reports (Washington, D.C. : 1974).
99(5):435-436
[PMID] 19313434.
1984
Perinatal and maternal mortality in a religious group avoiding obstetric care.
American journal of obstetrics and gynecology.
150(7):826-31
[PMID] 6507508.
1984
Progestogens, estrogen therapy, and endometrial cancer.
Annals of internal medicine.
100(2)
[PMID] 6691683.
1984
The Faith Assembly: a study of perinatal and maternal mortality.
Indiana medicine : the journal of the Indiana State Medical Association.
77(3):180-3
[PMID] 6707460.
1983
Abortion surveillance, 1979-1980.
MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.
32(2):1SS-7SS
[PMID] 6621605.
1982
Point of law: what are the legal implications of prescribing and administering FDA-approved drugs in nonapproved ways?
The Hospital medical staff.
11(2):15-8
[PMID] 10254209.
1980
Estrogen use in postmenopausal women.
The New England journal of medicine.
303(25):1477-8
[PMID] 7432409.
1979
Needle tract endometriosis: an unusual complication of amniocentesis.
Obstetrics and gynecology.
54(6):753-5
[PMID] 160025.
Grants
Jun 2024
ACTIVE
COllaboration for EQuity in Uterine Leiomyomas
Role: Co-Investigator
Funding: MAYO CLINIC
via NATL INST OF HLTH NICHD
Apr 2023
– Nov 2023
A multicenter, open-label, controlled study to investigate the effect of LF111 on bone mineral density (BMD) in adolescent and adult women in comparison with non-users of hormonal contraceptive methods.
Role: Principal Investigator
Funding: CHEMO RESEARCH
Sep 2022
– Sep 2023
A multicenter, open-label, controlled study to investigate the effect of LF111 on bone mineral density (BMD) in adolescent and adult women in comparison with non-users of hormonal contraceptive methods
Role: Principal Investigator
Funding: EXELTIS
Feb 2022
ACTIVE
A Phase 3, Multicenter, Open-Label, Single Arm Study of
MR-100A-01 in Women of Childbearing Potential to Evaluate
Contraceptive Efficacy and Safety
Role: Principal Investigator
Funding: MYLAN PHARMACEUTICALS INC
Dec 2021
ACTIVE
A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Dec 2020
ACTIVE
A Phase 3, Open-Label, Multi-Center, Single-Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel (MK-8415) Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Dec 2019
– Mar 2022
Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women with Polycystic Ovary Syndrome
Role: Principal Investigator
Funding: ABBVIE
Nov 2019
– Nov 2024
A Randomized Double-blind Placebo Controlled Phase 3 Trial to
Evaluate the Efficacy and Safety of Estetrol for the Treatment of
Moderate to Severe Vasomotor Symptoms in Postmenopausal
Women (E4Comfort Study II)
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via MITHRA PHARM ESTETRA SPRL
Jul 2019
– Feb 2023
An International Phase 3 Double-Blind, Placebo-controlled,
Randomized Withdrawal Study of Relugolix Coadministered
with Estradiol and Norethindrone Acetate in Women with
Heavy Menstrual Bleeding Associated with Uterine Fibroids
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES
via MYOVANT SCIENCES INC
Nov 2018
– Nov 2022
A Phase 3, Multicenter, Open-Label Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
Role: Principal Investigator
Funding: MEDICINES360
Oct 2018
– Mar 2022
An International Phase 3 Open-Label, Single-Arm, Long Term Efficacy and Safety Extension Study to Evaluate Relugolix Co Administered with Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids
Role: Principal Investigator
Funding: LBR REGULATORY
via MYOVANT SCIENCES INC
Apr 2018
– Oct 2020
Acurian ForSite Master Services Agreement
Role: Principal Investigator
Funding: ACURIAN
Nov 2017
– Nov 2018
The development of Phase 3 clinical protocol, assessing the safety and efficacy of LILETTA in the treatment of Heavy Menstrual Bleeding (HMB).
Role: Principal Investigator
Funding: MEDICINES360
Oct 2017
– Oct 2020
A Single-Arm, Phase III, Open-Label, Multicenter, Study in Women aged 18-35 Years of the Contraceptive Efficacy And Safety of Amphora? Contraceptive Vaginal Gel
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL PTY
Oct 2017
– Oct 2020
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) – (Placebo-Controlled, Double-Blind and Randomized Phase III Study of 24-Week Intravaginal Prasterone)
Role: Principal Investigator
Funding: ENDOCEUTICS
Mar 2017
– Feb 2019
FemBlocTM Permanent Contraceptive System
Role: Principal Investigator
Funding: FEMASYS
Mar 2017
– Oct 2020
An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids
Role: Principal Investigator
Funding: MYOVANT SCIENCES INC
Mar 2017
– Mar 2022
Multi-center, open-label, uncontrolled study to assess contraceptive efficacy and safety of Mirena during extended use beyond 5 years in women 18 to 35 years of age including a subgroup evaluation of a treatment effect on heavy menstrual bleeding
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Feb 2017
– Oct 2020
Prospective, Non-Interventional/Observational Registry of US Uterine Fibroids Patients
Role: Principal Investigator
Funding: ALLERGAN SALES
Oct 2016
– Oct 2020
A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone
Role: Principal Investigator
Funding: MITHRA PHARM ESTETRA SPRL
Oct 2016
– Oct 2021
A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)
Role: Principal Investigator
Funding: MILLENDO THERAPEUTICS INC
Jul 2016
– Jan 2017
A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study with an Interim Futility Analysis of Epelsiban in Patients with Adenomyosis
Role: Principal Investigator
Funding: GLAXOSMITHKLINE
Apr 2016
– Apr 2019
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED DOSE RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RAD1901 IN….
Role: Principal Investigator
Funding: RADIUS HEALTH INC
Oct 2015
– Sep 2018
A PHASE III SINGLE ARM CLINICAL TRIAL TO STUDY THE CONTRACEPTIVE EFFICACY AND SAFETY OF THE MK-8342B………..
Role: Principal Investigator
Funding: Merck Sharp & Dohme
Jan 2015
– Jan 2018
A SINGLE ARM, OPEN LABEL, MULYICENTER PAHSE 3 STUDY OF THE CONTRACEPTIVE EFFICACY, SAFETY AND TOLERABILITY OF THE …
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL PTY
via AGILE THERAPEUTICS
Dec 2013
– Dec 2016
A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY . . .
Role: Principal Investigator
Funding: HLTH DECISIONS
via THERAPEUTICSMD
Education
Obstetrics and Gynecology Residency
1982
·
Northwestern Memorial Hospital
Doctor of Medicine
1978
·
Columbia University College of Physicians And Surgeons
Contact Details
Phones:
- Business:
- (904) 244-3109
Emails:
- Business:
- andrew.kaunitz@jax.ufl.edu
Addresses:
- Business Street:
-
653-1 West 8th Street, L17
3rd Floor, LRC
Jacksonville FL 322096511